Cost Effectiveness of Palivizumab for Respiratory Syncytial Virus Prophylaxis in High-Risk Children

This study suggests that palivizumab prophylaxis against severe RSV infection in children at high risk may be cost effective from the NHS perspective (vs no prophylaxis), and that the positive clinical and economic benefits may persist beyond one RSV season. </AbstractSection> Copyright Adis Data Information BV 2007

MoreLess

Year of publication:	2007
Authors:	Nuijten, Mark ; Wittenberg, Wolfgang ; Lebmeier, Maximilian
Published in:	PharmacoEconomics. - Springer, ISSN 1170-7690. - Vol. 25.2007, 1, p. 55-71
Publisher:	Springer

More details

Extent:	text/html
Type of publication:	Article
Source:	RePEc - Research Papers in Economics

Persistent link: https://www.econbiz.de/10011001678